#2267

John Oyler

United States 58 years old Self-Made

Overview

Source of Wealth
Biotech
Industry
Healthcare
Residence
Reno, Nevada
Education
Massachusetts Institute of Technology (Bachelor of Arts/Science)
Stanford Graduate School of Business (Master of Business Administration)
Marital Status
Married

Assets

  • BeiGene, Ltd. Sponsored ADR
    140,152 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    3,938,181 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    169,000 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    0 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    61,030 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    71,923 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    157,500 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    77,000 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    90,751 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    100,776 shares @ -
    -
    ONC-US
  • BeiGene, Ltd. Sponsored ADR
    19,469 shares @ -
    -
    ONC-US

Biography

John Oyler is the CEO, cofounder and chairman of global oncology company BeOne Medicines. He owns nearly 5% of the publicly traded company.

BeOne Medicines, which was formerly called BeiGene, was founded in 2010 as a research and development firm. It went public on the Nasdaq in 2016 and listed in Hong Kong two years later.

Before he cofounded BeOne, Oyler helped start and then sell two companies in the U.S. and China.

He sold Telephia, a consumer telecom research firm he founded in 1997, to The Nielsen Co. for $449 million in 2007.

Oyler's next success came with drug discovery outsourcing company BioDuro, which he founded in 2005 and sold to PPD Inc. for $77 million in 2010.

About

BeOne has more than 40 drugs in its pipeline. Its blood cancer drug Brukinsa did more than $2 billion in U.S. sales in 2024.